Sanofi’s Qfitlia Gets India Nod For Bleeding Prevention In Haemophilia Patients; Experts Stress Access And Monitoring

Regeneron (REGN) reports Q3 earnings on Oct. 30, with full Dupixent profit inclusion for the first time. Q2 revenue was $4.29B, up 16.73%, with Dupixent sales at $6B. Analysts expect Q3 EPS of $16.20 and revenue of $4.56B. Collaboration margins and Eylea HD performance are key focuses.

Enable Injections received Japanese approval for its enFuse wearable drug delivery tech, used with Sanofi's Sarclisa for multiple myeloma. This marks the first on-body injector approval for an anticancer treatment in Japan. The device is also approved in the U.S. and Europe. Enable is working with drugmakers for future launches in various therapeutic areas.

Sanofi began constructing a EUR2bn insulin plant in Frankfurt, set to open in 2032. The facility will use advanced tech and secure long-term insulin supply for 80 countries. The investment, supported by EUR400m in public aid, aims to meet growing global demand. Sanofi supplies insulin to 15 million people annually, according to the company.

Sanofi's Qfitlia (fitusiran) received marketing approval in India for haemophilia A and B treatment. The drug, backed by Phase 3 trial results, offers a new approach by lowering antithrombin levels. Sanofi estimates 140,000 people in India may benefit, expanding prophylactic options. The company plans to support physician education on monitoring and dosing.

Sanofi and Teva's IBD drug, duvakitug, showed long-term clinical remission in a Phase IIb trial. Analysts highlight its high potency and potential advantages over competitors. MSD and Roche have also invested heavily in anti-TL1A drugs, with MSD's tulisokibart and Roche's afimkibart in Phase III trials.

Sanofi's Qfitlia (fitusiran) received marketing approval in India for treating hemophilia A and B in adults and adolescents, according to the company.